Thyroid gland undifferentiated (anaplastic) carcinoma
MONDO:0006468A primary carcinoma of the thyroid gland composed of undifferentiated cells. The malignant cells demonstrate evidence of epithelial differentiation, either by immunohistochemistry or electron microscopic studies. Microscopically, in the majority of cases there is a mixture of spindle, epithelioid, and giant cells. The vast majority of the patients present with a rapidly enlarging neck mass. The clinical course is usually aggressive.
Also known as: Dedifferentiated thyroid gland carcinoma, anaplastic carcinoma of the thyroid, anaplastic carcinoma of the thyroid gland, anaplastic carcinoma of thyroid, anaplastic carcinoma of thyroid gland, anaplastic thyroid cancer, anaplastic thyroid carcinoma, anaplastic thyroid gland carcinoma
2787 clinical trials for this condition and its sub-types, 35 tagged with Thyroid gland undifferentiated (anaplastic) carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedThis study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New targeted drug shows promise for BRAF-Mutant cancers in early trial
Disease control CompletedThis early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is comple…
Phase 1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC